Imagion Biosystems Limited (IBXXF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Imagion Biosystems Limited (IBXXF) with AI Score 42/100 (Weak). Imagion Biosystems Limited is a medical imaging technology company focused on cancer detection and therapy monitoring using superparamagnetic relaxometry. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Imagion Biosystems Limited (IBXXF) Healthcare & Pipeline Overview
Imagion Biosystems Limited develops and seeks to commercialize medical imaging technologies for cancer diagnostics, focusing on its MagSense technology currently in Phase I clinical trials for HER2 breast cancer. The company operates in the nanotechnology and biotechnology sectors, aiming to improve cancer detection and monitoring through advanced imaging solutions.
Investment Thesis
Imagion Biosystems Limited presents a high-risk, high-reward investment opportunity within the cancer diagnostics sector. The company's MagSense technology, currently in Phase I clinical trials, holds promise for improving the detection of HER2-positive breast cancer. Successful completion of clinical trials and subsequent regulatory approval could drive significant value. However, the company's negative profit margin of -16746.2% and negative gross margin of -2293.6% highlight its reliance on external funding. Key value drivers include the successful advancement of MagSense through clinical trials, strategic partnerships, and potential acquisition by a larger player in the medical imaging space. The company's low market capitalization of $0.00B and negative beta of -0.14 indicate high volatility and sensitivity to market conditions.
Based on FMP financials and quantitative analysis
Key Highlights
- MagSense is in Phase I clinical trials for the treatment of HER2 breast cancers, representing a key milestone in the company's development.
- Collaborative research program with Patrys Limited focuses on enhancing brain tumor imaging and diagnosis, expanding the application of Imagion's technology.
- Joint development agreement with Global Cancer Technology, Inc. aims to develop nanoscintillator technology for breast cancer treatment, diversifying the company's pipeline.
- The company's negative profit margin of -16746.2% indicates significant ongoing research and development expenses.
- The company's negative gross margin of -2293.6% reflects the current stage of development and lack of revenue-generating products.
Competitors & Peers
Strengths
- Proprietary MagSense technology in Phase I clinical trials.
- Focus on a specific niche within the cancer diagnostics market (HER2-positive breast cancer).
- Collaborative research programs with Patrys Limited and Global Cancer Technology, Inc.
- Experienced management team with expertise in nanotechnology and biotechnology.
Weaknesses
- Negative profit margin and gross margin.
- Reliance on external funding.
- Early stage of development (Phase I clinical trials).
- Limited revenue generation.
Catalysts
- Upcoming: Announcement of Phase I clinical trial results for MagSense.
- Ongoing: Progression of MagSense through clinical trials.
- Ongoing: Strategic partnerships and collaborations.
- Ongoing: Development of PrecisionMRX.
- Ongoing: Potential acquisition by a larger player.
Risks
- Potential: Failure to secure additional funding.
- Potential: Unsuccessful clinical trials.
- Potential: Regulatory hurdles and delays.
- Ongoing: Competition from established players in the medical imaging market.
- Ongoing: Negative profit margin and gross margin.
Growth Opportunities
- Advancement of MagSense through Clinical Trials: The successful completion of Phase I clinical trials for MagSense and progression to Phase II and Phase III trials represents a significant growth opportunity. Positive clinical data could attract partnerships with larger pharmaceutical companies and accelerate regulatory approval. The market for HER2-positive breast cancer diagnostics is substantial, offering a significant revenue potential for Imagion Biosystems upon commercialization. Timeline: Ongoing, with Phase I results expected in the near term.
- Expansion of MagSense to Other Cancer Types: Imagion Biosystems can expand the application of its MagSense technology to detect other types of cancer beyond HER2-positive breast cancer. This would involve developing new targeting agents that bind to specific biomarkers on different cancer cells. The market for cancer diagnostics is broad, and expanding the application of MagSense could significantly increase the company's revenue potential. Timeline: 2-3 years for research and development of new targeting agents.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with pharmaceutical companies, research institutions, and other healthcare providers can accelerate the development and commercialization of Imagion's technologies. These partnerships can provide access to funding, expertise, and distribution channels. The company already has collaborations with Patrys Limited and Global Cancer Technology, Inc., and further partnerships could drive growth. Timeline: Ongoing.
- Development of PrecisionMRX: The development of PrecisionMRX, an iron oxide nanoparticle for cancer detection, represents another growth opportunity for Imagion Biosystems. This technology could complement MagSense and provide a broader range of imaging solutions. Successful development and commercialization of PrecisionMRX could diversify the company's revenue streams. Timeline: 3-5 years for research, development, and regulatory approval.
- Potential Acquisition by a Larger Player: Given its innovative technology and focus on cancer diagnostics, Imagion Biosystems could be an attractive acquisition target for a larger player in the medical imaging or pharmaceutical industry. An acquisition would provide Imagion's shareholders with a significant return on investment. The medical imaging market is consolidating, and larger companies are seeking to acquire innovative technologies to expand their product portfolios. Timeline: Uncertain, but potential within the next 3-5 years.
Opportunities
- Successful completion of clinical trials and regulatory approval of MagSense.
- Expansion of MagSense to other cancer types.
- Strategic partnerships and collaborations.
- Development of PrecisionMRX.
Threats
- Competition from established players in the medical imaging market.
- Regulatory hurdles and delays.
- Failure to secure additional funding.
- Unsuccessful clinical trials.
Competitive Advantages
- Proprietary superparamagnetic relaxometry technology.
- MagSense technology in Phase I clinical trials.
- Collaborative research programs with Patrys Limited and Global Cancer Technology, Inc.
- Focus on a specific niche within the cancer diagnostics market (HER2-positive breast cancer).
About IBXXF
Imagion Biosystems Limited, incorporated in 2016 and based in San Diego, California, is a medical imaging technology company specializing in cancer detection and therapy monitoring. The company's core technology revolves around superparamagnetic relaxometry, a technique that uses nanoparticles to enhance the sensitivity and specificity of medical imaging. Their primary focus is the development of MagSense, an imaging agent currently in Phase I clinical trials for detecting HER2-positive breast cancer. MagSense utilizes nanoparticles that bind to HER2 receptors on cancer cells, allowing for more precise detection through MRI. In addition to MagSense, Imagion Biosystems is developing PrecisionMRX, an iron oxide nanoparticle designed to improve cancer detection. The company also engages in collaborative research, including a program with Patrys Limited to enhance brain tumor imaging and diagnosis and a joint development agreement with Global Cancer Technology, Inc. to develop nanoscintillator technology for breast cancer treatment. Imagion's activities span nanotechnology, biotechnology, and cancer diagnostics, reflecting its commitment to advancing cancer imaging and treatment through innovative technologies.
What They Do
- Develops MagSense, an imaging agent in Phase I clinical trials for HER2-positive breast cancer detection.
- Utilizes superparamagnetic relaxometry technology for enhanced medical imaging.
- Focuses on cancer diagnostics and therapy monitoring.
- Engages in nanotechnology and biotechnology research.
- Develops PrecisionMRX, an iron oxide nanoparticle for cancer detection.
- Collaborates with Patrys Limited to enhance brain tumor imaging and diagnosis.
- Partners with Global Cancer Technology, Inc. to develop nanoscintillator technology for breast cancer treatment.
Business Model
- Develops and seeks to commercialize medical imaging technologies for cancer detection.
- Generates revenue through potential licensing agreements and partnerships.
- Aims to generate revenue through future sales of MagSense and PrecisionMRX upon regulatory approval.
- Secures funding through grants, equity financing, and potential future debt financing.
Industry Context
Imagion Biosystems operates in the medical diagnostics and research industry, a sector characterized by rapid innovation and increasing demand for advanced imaging technologies. The global cancer diagnostics market is projected to reach billions of dollars by 2026, driven by the rising incidence of cancer and the need for early and accurate detection. The competitive landscape includes established players like AGNPF, APLIF, CSOC, CSSI, and GENPF, as well as smaller, specialized companies focused on niche areas. Imagion Biosystems aims to differentiate itself through its superparamagnetic relaxometry technology and its focus on improving cancer detection and therapy monitoring.
Key Customers
- Hospitals and medical imaging centers.
- Oncologists and other healthcare professionals.
- Pharmaceutical companies seeking to improve cancer diagnostics.
- Research institutions and universities.
Financials
Chart & Info
Imagion Biosystems Limited (IBXXF) stock price: Price data unavailable
Latest News
-
Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
Yahoo! Finance: IBXXF News · Feb 3, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IBXXF.
Price Targets
Wall Street price target analysis for IBXXF.
MoonshotScore
What does this score mean?
The MoonshotScore rates IBXXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Robert Romeo Proulx
CEO
Robert Romeo Proulx serves as the CEO of Imagion Biosystems Limited. His background includes extensive experience in the biotechnology and medical device industries. He has held leadership positions in various companies, focusing on strategic planning, product development, and commercialization. Proulx's expertise spans areas such as oncology, diagnostics, and medical imaging. His educational background includes advanced degrees in science and business administration, providing him with a strong foundation for leading a company focused on innovative medical technologies.
Track Record: Under Robert Romeo Proulx's leadership, Imagion Biosystems has advanced its MagSense technology into Phase I clinical trials for HER2-positive breast cancer. He has also overseen the establishment of strategic partnerships with Patrys Limited and Global Cancer Technology, Inc. Proulx has focused on securing funding to support the company's research and development efforts and has guided the company through key milestones in its clinical development program.
IBXXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Imagion Biosystems Limited may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher price volatility due to lower trading volume.
- Potential for wider bid-ask spreads and slippage.
- Increased risk of fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's OTC Markets profile and disclosure statements.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Check for any regulatory actions or legal proceedings against the company.
- Company is incorporated in the US (San Diego, California).
- MagSense technology is in Phase I clinical trials.
- Collaborative research programs with Patrys Limited and Global Cancer Technology, Inc.
- Company has a CEO (Robert Romeo Proulx) with experience in the biotechnology industry.
- Company has a business address and contact information.
Imagion Biosystems Limited Stock: Key Questions Answered
What does Imagion Biosystems Limited do?
Imagion Biosystems Limited is a medical imaging company focused on developing and commercializing technologies for cancer detection and therapy monitoring. The company's core technology, MagSense, utilizes superparamagnetic relaxometry to enhance the sensitivity and specificity of medical imaging. MagSense is currently in Phase I clinical trials for the detection of HER2-positive breast cancer. The company aims to improve cancer diagnosis and treatment outcomes through its innovative imaging solutions.
What do analysts say about IBXXF stock?
As of 2026-03-16, there is no readily available analyst consensus on IBXXF stock, likely due to its OTC listing and early stage of development. Key valuation metrics such as P/E ratio (-1.60) and profit margin (-16746.2%) are currently negative, reflecting the company's ongoing research and development expenses. Growth considerations revolve around the successful advancement of MagSense through clinical trials and potential partnerships. Investors should conduct their own thorough due diligence before making any investment decisions.
What are the main risks for IBXXF?
The main risks for Imagion Biosystems Limited include the potential failure to secure additional funding, the risk of unsuccessful clinical trials for MagSense, and regulatory hurdles and delays. The company also faces competition from established players in the medical imaging market. Additionally, the company's negative profit margin and gross margin highlight its reliance on external funding and the uncertainty of future revenue generation. Investing in IBXXF carries a high degree of risk due to its OTC listing and early stage of development.
What is Imagion Biosystems Limited's drug pipeline status?
Imagion Biosystems Limited's primary focus is on its MagSense technology, which is currently in Phase I clinical trials for the detection of HER2-positive breast cancer. The company is also developing PrecisionMRX, an iron oxide nanoparticle for cancer detection. The successful completion of Phase I trials for MagSense and progression to Phase II and Phase III trials would represent significant milestones. The company's pipeline is focused on improving cancer diagnostics through advanced imaging solutions.
How does Imagion Biosystems Limited navigate regulatory approval processes?
Imagion Biosystems Limited is currently navigating the regulatory approval process for its MagSense technology, which is in Phase I clinical trials. The company will need to demonstrate the safety and efficacy of MagSense through clinical trials and submit a comprehensive regulatory filing to the FDA or other regulatory agencies. The regulatory approval process can be lengthy and complex, and there is no guarantee that MagSense will be approved. The company's strategy includes working closely with regulatory experts and conducting rigorous clinical trials to support its regulatory filings.
What are the key factors to evaluate for IBXXF?
Imagion Biosystems Limited (IBXXF) currently holds an AI score of 42/100, indicating low score. Key strength: Proprietary MagSense technology in Phase I clinical trials.. Primary risk to monitor: Potential: Failure to secure additional funding.. This is not financial advice.
How frequently does IBXXF data refresh on this page?
IBXXF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IBXXF's recent stock price performance?
Recent price movement in Imagion Biosystems Limited (IBXXF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary MagSense technology in Phase I clinical trials.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be limited due to the company's OTC listing.
- Analyst consensus is not available due to limited coverage.
- The competitive landscape is based on publicly available information and may not be exhaustive.